The Wnt β-catenin signaling pathway is blocked in HRpositive and TNBC breast cancer subtypes by different members of the miR-130 family | [Bioscience Research • 2024]

Author(s):

1. Fatima Abdullah M Asiri: Department of Biological Sciences, Faculty of Science, King Abdulaziz University,Jeddah,Saudi Arabia

2. Hani M. Ali: Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia; Princess Dr. Najla Bint Saud Al- Saud Center for Excellence Research in Biotechnology, King Abdulaziz University, Jeddah, Saudi Arabia

3. Mohammed Abdullah Ali almousa: MOH-Aseer Central Hospital,Ministry Of Health. Aseer,Saudi Arabia

4. Mohammed A. Al-Matary: Department of Biological Sciences, Faculty of Science, King Abdulaziz University,Jeddah,Saudi Arabia

5. Ahmed Bahieldin: Department of Biological Sciences, Faculty of Science, King Abdulaziz University,Jeddah,Saudi Arabia

Abstract:

MiRNAs (miRNA) expression is dysregulated in breast cancer, and identifying the differentially expressed miRNAs (DEMs) is essential for developing novel biomarkers. The present study profiled the circulating miRNAs in breast cancer patients from the Asir region (KSA) by high-throughput RNA sequencing. The study included 11 early-stage breast cancer patients (8 hormone-positive or HR+ve and 3 TNBC) and four normal controls. The hsa-miR-130a-3p and hsamiR-301a-3p were under-expressed in HR+ve and TNBC subtypes and might act as tumour suppressor miRNAs (tsmiRs). The two tsmiRs are closely related and belong to the miR-130 family. Pathways that are blocked by hsa-miR130a-3p in the HR+ve subtype are blocked by hsa-miR-301a-3p in the TNBC subtype. In the Wnt signalling pathway, hsa-miR-130a-3p down-regulates T-cell factor (TCF7)/LEF1 transcription factor in the HR+ve subtype, while hsa-miR301a-3p down regulates dishevelled (DVL2), and lymphoid enhancer-binding factor (LEF1) in the TNBC subtype. The two putative tsmiRs could have potential therapeutic applications by targeting the Wnt signalling pathway in breast cancer patients, especially in TNBC patients, due to the lack of effective treatment and poor prognosis of TNBCs.

Page(s): 308-313

DOI: DOI not available

Published: Journal: Bioscience Research, Volume: 21, Issue: 2, Year: 2024

Keywords:

Breast Cancer , microRNA , Tumor suppressor miRNA , TNBC , Therapeutic miRNA candidates , Hormonepositive , Asir region

References:

[1] Arun R.P.,Cahil H.F.,Marcato P. .2022 .Breast cancer subtype-specific miRNAs: Networks, impacts, and the potential for intervention. Biomedicines, 10(3) : 651.

[2] Causin R. L.,Lengert A.V.H.,Gomes I.N.F.,De Freitas A.J.A.,Rosa M.N.,Reis R.D.,Reis R.M.,Marques M.M.C. .2023 .MicroRNA-130a-3p inhibition suppresses cervical cancer cell progression. Oncology Reports, 49 : 109.

[3] Filipow S.,Laczmanski L. .2019 .Blood circulating miRNAs as cancer biomarkers for diagnosis and. , : .

Citations

Downloads

Views